CLINICAL_TRIALS
trial_result
· 2022-05-17
Clinical Trial Update: The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis [Phase 2]
Summary
Phase 2 trial update on the long-term safety and efficacy of olokizumab (CDP6038) in active rheumatoid arthritis.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: UCB BIOSCIENCES, Inc. | Conditions: Rheumatoid Arthritis | Phase 2 | Status: TERMINATED | Results posted: 2022-05-17